[Form 4] Immunome, Inc. Insider Trading Activity

Rhea-AI Filing Summary

Insider transaction summary for Immunome, Inc. (IMNM): Reporting person Jack Higgins, identified as an officer with the title Chief Scientific Officer, reported transactions dated 09/10/2025. He acquired 22,000 common shares by exercise/transaction code M at a price of $1.35 per share, bringing his reported direct beneficial ownership in common stock to 40,729 shares. The filing also reports derivative holdings: an employee stock option with a conversion/exercise price of $1.35 exercisable beginning 06/23/2032 and, following the reported transactions, 151,840 derivative securities are shown as beneficially owned. Vesting terms state 25% vested on 05/01/2023 with the remainder vesting in 36 equal monthly installments.

Positive

• Officer acquired 22,000 shares at $1.35 on 09/10/2025, increasing direct ownership to 40,729 shares
• Vesting schedule disclosed (25% vested 05/01/2023; remainder in 36 monthly installments), providing transparency on timing
• Derivative holdings reported with 151,840 securities beneficially owned following the transaction, clarifying total exposure

Negative

• None.

Insights

Securities/Fundamental Analyst

TL;DR: Routine insider option exercise and vesting increased executive's direct and derivative holdings; no new material change to control.

The Form 4 reports an officer-level option exercise/issuance of 22,000 common shares at $1.35 on 09/10/2025, increasing direct holdings to 40,729 shares and leaving 151,840 derivative securities reported post-transaction. The disclosed vesting schedule (25% on 05/01/2023 then 36 monthly installments) explains the timing of share acquisition. This appears operationally routine: typical employee equity vesting and option exercise rather than a corporate event likely to alter company control or capital structure materially. No cash-proceeds, debt changes, or extraordinary transfers are disclosed.

Corporate Governance Expert

TL;DR: Disclosure aligns with Section 16 reporting; transaction appears consistent with standard executive compensation vesting.

The filer is identified as an officer (Chief Scientific Officer) and the filing was signed by an attorney-in-fact. The explanation clarifies the vesting schedule, indicating the transaction arises from scheduled vesting and/or option exercise. From a governance perspective, the filing fulfills Section 16 transparency requirements. The record shows no related-party transfers, sales, or exceptions that would raise immediate governance concerns based on the submitted content.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Higgins Jack

(Last) (First) (Middle)

C/O IMMUNOME, INC.

18702 N. CREEK PARKWAY, SUITE 100

(Street)

BOTHELL WA 98011

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Immunome Inc. [ IMNM ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Scientific Officer

3. Date of Earliest Transaction (Month/Day/Year)
09/10/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/10/2025		M		22,000	A	$1.35	40,729	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock option (right to buy)	$1.35	09/10/2025		M			22,000	(1)	06/23/2032	Common Stock	22,000	$0	151,840	D

Explanation of Responses:

1. 25% of the shares vested on May 1, 2023, and the remaining shares shall vest in 36 equal monthly installments thereafter.

	/s/ Sandra Stoneman, Attorney-in-Fact	09/11/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What transaction did Jack Higgins report for IMNM on 09/10/2025?

The Form 4 shows an acquisition of 22,000 common shares at $1.35 per share on 09/10/2025 under transaction code M.

How many IMNM shares does the reporting person beneficially own after the transaction?

The filing reports 40,729 common shares beneficially owned following the reported transaction.

What derivative holdings were reported by the insider in the IMNM Form 4?

The Form 4 reports an employee stock option with a $1.35 exercise price exercisable from 06/23/2032 and shows 151,840 derivative securities beneficially owned after the transaction.

What is the vesting schedule disclosed in the IMNM filing?

The explanation states 25% of the shares vested on 05/01/2023 and the remaining shares vest in 36 equal monthly installments thereafter.

What is the reporting person’s role at Immunome (IMNM)?

The Form 4 identifies the reporting person as an officer with the title Chief Scientific Officer.